ARID1A and cancer: Given that ARID1A-mutated GC cancers expressed PD-L1 more highly than ARID1A wild-type GC cancers, which contribute to the more active immunotherapeutic responsiveness and better survival prognosis, ARID1A mutation could additionally be a useful biomarker for identifying GC cancer patients responsive to immunotherapy.